Sage Therapeutics, Inc. (NASDAQ:SAGE) Q3 2023 Earnings Call Transcript
Operator: Good morning. Welcome to Sage Therapeutics' Third Quarter 2023 Conference Call. [Operator Instructions].
Sage Therapeutics Inc. (SAGE)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Palo Alto Investors William Leland Edwards | 1,005,776 | $20,698,870 | +18% | 1.95% |
| 2. | Samlyn Capital Robert Pohly | 739,867 | $15,226,463 | 0.24% | |
| 3. | Alyeska Investment Group Anand Parekh | 528,821 | $10,883,136 | 0.07% | |
| 4. | Fisher Asset Management Ken Fisher | 399,619 | $8,224,159 | -8% | 0% |
| 5. | Citadel Investment Group Ken Griffin | 380,268 | $7,825,915 | +70% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.64 | 2,000 | 3,000 | 2023-08-09 | Filing | ||
| $50.50 | 1,000 | 1,000 | 2023-05-09 | Filing | ||
| $34.48 | 14,500 | 46,940 | 2022-11-10 | Filing | ||
| $31.45 | 8,000 | 8,000 | 2022-05-05 | Filing | ||
| $43.15 | 23,640 | 32,440 | 2021-08-05 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $44.90 | 3,838 | 121,981 | 2023-02-10 | Filing | ||
| $44.47 | 7,805 | 125,819 | 2023-02-10 | Filing | ||
| $160.58 | 8,000 | 2,535 | 2019-08-15 | Filing | ||
| $171.39 | 475 | 12,115 | 2019-05-29 | Filing | ||
| $170.40 | 400 | 12,590 | 2019-05-29 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 7,696,055 | $158,384,813 | 0.01% | |
| 2. | 6,572,260 | $135,257,109 | 0.02% | |
| 3. | 5,208,002 | $107,180,681 | 0% | |
| 4. | 5,149,482 | $105,976,340 | 2.23% | |
| 5. | 4,378,467 | $90,108,851 | 0% |
News See All
Aristotle Atlantic’s Large Cap Growth Strategy Sold Sage Therapeutics (SAGE) on Uncertainty Surrounding the Company
Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” third quarter 2023 investor letter. A copy of the same can be downloaded here.
5 Oversold NASDAQ Stocks to Buy
San Francisco, California-based Vir Biotechnology, Inc. (NASDAQ:VIR) is a commercial-stage immunology company focused on the development of therapies to treat and prevent serious infectious diseases.
10 Oversold Biotech Stocks to Buy
In this article, we will take a look at the 10 oversold biotech stocks to buy.
Sage Therapeutics, Inc. (NASDAQ:SAGE) Q1 2023 Earnings Call Transcript
Operator: Good morning. Welcome to the Sage Therapeutics' First Quarter 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode.
Sage Therapeutics, Inc. (NASDAQ:SAGE) Q4 2022 Earnings Call Transcript
Operator: Good morning. Welcome to the Sage Therapeutics' Fourth Quarter and Full-Year 2022 Financial Results Conference Call. Currently, all participants are in a listen-only mode.
Sage Therapeutics, Inc. (NASDAQ:SAGE) Q3 2022 Earnings Call Transcript
Operator: Good morning. Welcome to the Sage Therapeutics' Third Quarter 2022 Financial Results Conference Call. Currently, all participants are in a listen-only mode.
Hedge Fund and Insider Trading News: Steve Cohen, Dan Loeb, Sachem Head Capital Management, AIM Capital, Lions Gate Entertainment Corp. (LGF), Truist Financial Corp (TFC), and More
In the 18 months since billionaire hedge-fund manager Steve Cohen bought the New York Mets, the baseball world has wondered how the sport’s wealthiest owner would use his vast resources and financial...
10 Market-Moving Stocks to Watch on Monday
Following April's tumultuous trading, investors are preparing themselves for more market-moving developments this week.
10 Best Healthcare Stocks To Buy In 2022
The post-COVID world has highlighted several existing and emerging healthcare trends, such as shifting consumer preferences, the collaboration of life sciences and healthcare, new digital health technologies...
Billionaire Hedge Funds
